Physician profile
Joyce Tsai
NPI 1447513213
$444.74
in general payments reported to CMS, 2019-2025
11 companies · $95.41 in 2025
The $95.41 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.71 · 2022: $114 · 2023: $70.58 · 2024: $102 · 2025: $95.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $144.78 | 2021-2025 | |
| Lilly USA, LLC | $63.43 | 2021-2025 | Kisunla, Emgality |
| Lundbeck LLC | $48.05 | 2022-2024 | Vyepti, Rexulti |
| Neurelis, INC. | $39.24 | 2022-2023 | Valtoco |
| Ucb, INC. | $38.41 | 2022-2025 | Briviact |
| Aucta Pharmaceuticals, INC. | $27.32 | 2024 | Motpoly Xr |
| Livanova USA, INC. | $22.82 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.01 | 2025 | Qelbree |
| Abbvie INC. | $14.42 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $13.69 | 2024 | Austedo Xr |
| Corium, LLC | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.